As US companies raise concerns about India’s pharma sector and the country’s “deteriorating” intellectual property rights (IPR) regime, an Indian industry lobby has refuted the claims and pointed out that the IP regime, “even in the US is litigious and more unpredictable than India”, as evident by the decisions taken by its Supreme Court.
The Indian Pharmaceutical Alliance (IPA), in a note furnished to corporates participating in the India-US CEO forum and the government, has said that country’s intellectual patent regime conforms to the WTO norms and “they are using the US regime as benchmark to evaluate India’s intellectual patent regime. But India has never agreed to conform to the United States standards… accepted international standards as embodied in the Trade Related Aspects of Intellectual Property Rights (TRIPs) 1994 Agreement… these concerns are misplaced.”
📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines